CT 071
Alternative Names: CT-071; GPRC5D targeted CAR T cell therapy - CARsgen TherapeuticsLatest Information Update: 21 Feb 2025
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Leukaemia; Multiple myeloma
Most Recent Events
- 21 Feb 2025 Updated efficacy and adverse event data from a phase 0 trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
- 06 Nov 2024 Efficacy and adverse events data from phase-0 for Multiple myeloma released by CARsgen Therapeutics
- 30 Oct 2024 The US FDA lifts the clinical holds hold on clinical trials of CT 071 in USA